The FDA last week approved Novo Nordisk’s Ozempic to “reduce the risk of major adverse cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease,” an expansion of the drug’s current type 2 diabetes indication. For the treatment of type 2 diabetes, Ozempic currently holds preferred formulary status for 44% of all covered lives.

SOURCE: MMIT Analytics, as of 1/22/20